2009
DOI: 10.1001/archdermatol.2009.283
|View full text |Cite
|
Sign up to set email alerts
|

Lichen Planopilaris Treated With a Peroxisome Proliferator–Activated Receptor γ Agonist

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
87
0
2

Year Published

2011
2011
2023
2023

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 108 publications
(89 citation statements)
references
References 17 publications
0
87
0
2
Order By: Relevance
“…Based on these findings in mice, clinicians have successfully treated refractory lichen planopilaris using pioglitazone hydrochloride. 35 Although this is a potentially important development, confirmatory case reports and clinical trials are needed.…”
Section: Lymphocytic Alopeciamentioning
confidence: 99%
“…Based on these findings in mice, clinicians have successfully treated refractory lichen planopilaris using pioglitazone hydrochloride. 35 Although this is a potentially important development, confirmatory case reports and clinical trials are needed.…”
Section: Lymphocytic Alopeciamentioning
confidence: 99%
“…31 This is especially pertinent given the emerging role of peroxisome proliferator-activator receptor (PPAR)-c in the aetiopathogenesis of scarring alopecias such as LPP. 72,73 Clinically, CCCA presents as a slow-growing area of alopecia involving the crown and/or vertex scalp regions 3,74 (Figs 4b and 7). The involved area appears smooth and shiny, with loss of follicular orifices.…”
Section: Central Centrifugal Cicatricial Alopeciamentioning
confidence: 99%
“…73 The aetiology of FFA remains unknown. Various hypotheses exist including environmental and genetic factors.…”
Section: Lichen Planopilaris and Frontal Fibrosing Alopeciamentioning
confidence: 99%
“…From the 326 responders, 16 were excluded from analysis because of a history of alopecia areata, lupus, and/or other hair loss pattern that was consistent with either of these types of hair loss. The NAHRS central hair loss scale was used to grade central hair loss in all responders.…”
Section: Demographic Data and Clinical Findingsmentioning
confidence: 99%